NASDAQ:INFI Infinity Pharmaceuticals Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Infinity Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.11 +0.01 (+0.91 %) (As of 09/21/2020 12:00 AM ET) Add Compare Share Today's Range$1.08Now: $1.11▼$1.1250-Day Range$0.89MA: $1.10▼$1.3452-Week Range$0.60Now: $1.11▼$1.68Volume203,764 shsAverage Volume428,067 shsMarket Capitalization$65.35 millionP/E RatioN/ADividend YieldN/ABeta1.92 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Infinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for people with cancer in the United States. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib, as well as duvelisib program, including DUO study that is in randomized and monotherapy Phase III clinical study for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma; PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate; and AbbVie Inc. to develop and commercialize products containing duvelisib in oncology indications., as well as collaboration agreements with Arcus Biosciences, Inc. and Bristol-Myers Squibb Company. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingInfinity Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $2.17, Infinity Pharmaceuticals has a forecasted upside of 95.2% from its current price of $1.11.Amount of Analyst CoverageInfinity Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Community Rank Outperform VotesInfinity Pharmaceuticals has received 352 “outperform” votes. (Add your “outperform” vote.)Underperform VotesInfinity Pharmaceuticals has received 530 “underperform” votes. (Add your “underperform” vote.)Community SentimentInfinity Pharmaceuticals has received 60.09% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Infinity Pharmaceuticals and other stocks. Vote “Outperform” if you believe INFI will outperform the S&P 500 over the long term. Vote “Underperform” if you believe INFI will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldInfinity Pharmaceuticals does not currently pay a dividend.Dividend GrowthInfinity Pharmaceuticals does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Infinity Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 13.77% of the stock of Infinity Pharmaceuticals is held by insiders.Percentage Held by Institutions47.23% of the stock of Infinity Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Infinity Pharmaceuticals are expected to decrease in the coming year, from ($0.64) to ($0.75) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Infinity Pharmaceuticals is -1.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Infinity Pharmaceuticals is -1.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInfinity Pharmaceuticals has a P/B Ratio of 7.93. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.3Community Rank: 2.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.27 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:INFI Previous Symbol CUSIP45665G30 CIK1113148 Webwww.infi.com Phone617-453-1000Debt Debt-to-Equity RatioN/A Current Ratio5.05 Quick Ratio5.05Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$3.05 million Price / Sales21.43 Cash FlowN/A Price / Cash FlowN/A Book Value$0.14 per share Price / Book7.93Profitability EPS (Most Recent Fiscal Year)($0.83) Net Income$-47,060,000.00 Net Margins-2,999.17% Return on Equity-1,358.77% Return on Assets-80.72%Miscellaneous Employees25 Outstanding Shares58,871,000Market Cap$65.35 million Next Earnings Date11/4/2020 (Estimated) OptionableOptionable $1.11 +0.01 (+0.91 %) (As of 09/21/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive INFI News and Ratings via Email Sign-up to receive the latest news and ratings for INFI and its competitors with MarketBeat's FREE daily newsletter. Infinity Pharmaceuticals (NASDAQ:INFI) Frequently Asked Questions How has Infinity Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)? Infinity Pharmaceuticals' stock was trading at $1.01 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, INFI stock has increased by 9.9% and is now trading at $1.11. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Infinity Pharmaceuticals? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Infinity Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Infinity Pharmaceuticals. When is Infinity Pharmaceuticals' next earnings date? Infinity Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020. View our earnings forecast for Infinity Pharmaceuticals. How were Infinity Pharmaceuticals' earnings last quarter? Infinity Pharmaceuticals Inc. (NASDAQ:INFI) announced its quarterly earnings results on Thursday, July, 30th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.20) by $0.04. The biotechnology company had revenue of $0.36 million for the quarter, compared to the consensus estimate of $0.20 million. Infinity Pharmaceuticals had a negative return on equity of 1,358.77% and a negative net margin of 2,999.17%. View Infinity Pharmaceuticals' earnings history. What price target have analysts set for INFI? 3 brokerages have issued 12-month price objectives for Infinity Pharmaceuticals' shares. Their forecasts range from $1.00 to $3.00. On average, they expect Infinity Pharmaceuticals' stock price to reach $2.17 in the next twelve months. This suggests a possible upside of 95.2% from the stock's current price. View analysts' price targets for Infinity Pharmaceuticals. Are investors shorting Infinity Pharmaceuticals? Infinity Pharmaceuticals saw a decline in short interest during the month of August. As of August 31st, there was short interest totaling 77,100 shares, a decline of 48.4% from the August 15th total of 149,300 shares. Based on an average trading volume of 839,700 shares, the short-interest ratio is presently 0.1 days. Approximately 0.1% of the company's shares are sold short. View Infinity Pharmaceuticals' Short Interest. Who are some of Infinity Pharmaceuticals' key competitors? Some companies that are related to Infinity Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Immunomedics (IMMU), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX) and Exelixis (EXEL). View all competitors. What other stocks do shareholders of Infinity Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Infinity Pharmaceuticals investors own include Continental Resources (CLR), Rex Energy (REXX), Aerie Pharmaceuticals (AERI), Gilead Sciences (gild), Inovio Pharmaceuticals (INO), Novavax (NVAX), AVEO Pharmaceuticals (AVEO), ImmunoGen (IMGN), Opko Health (OPK) and Geron (GERN). Who are Infinity Pharmaceuticals' key executives? Infinity Pharmaceuticals' management team includes the following people: Ms. Adelene Q. Perkins, Chairman & CEO (Age 59)Dr. Lawrence E. Bloch, Pres & Treasurer (Age 53)Dr. Jeffery L. Kutok, Sr. VP & Chief Scientific Officer (Age 52)Mr. Seth A. Tasker, VP, Gen. Counsel & Sec. (Age 40)Ms. Melissa Hackel, VP of Fin. What is Infinity Pharmaceuticals' stock symbol? Infinity Pharmaceuticals trades on the NASDAQ under the ticker symbol "INFI." Who are Infinity Pharmaceuticals' major shareholders? Infinity Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Bridgeway Capital Management Inc. (0.71%), Jacobs Levy Equity Management Inc. (0.47%) and Russell Investments Group Ltd. (0.07%). Company insiders that own Infinity Pharmaceuticals stock include Adelene Q Perkins, Bvf Partners L P/Il and Value Fund L P Biotechnology. View institutional ownership trends for Infinity Pharmaceuticals. Which institutional investors are buying Infinity Pharmaceuticals stock? INFI stock was purchased by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Jacobs Levy Equity Management Inc., and Bridgeway Capital Management Inc.. Company insiders that have bought Infinity Pharmaceuticals stock in the last two years include Bvf Partners L P/Il, and Value Fund L P Biotechnology. View insider buying and selling activity for Infinity Pharmaceuticals. How do I buy shares of Infinity Pharmaceuticals? Shares of INFI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Infinity Pharmaceuticals' stock price today? One share of INFI stock can currently be purchased for approximately $1.11. How big of a company is Infinity Pharmaceuticals? Infinity Pharmaceuticals has a market capitalization of $65.35 million and generates $3.05 million in revenue each year. The biotechnology company earns $-47,060,000.00 in net income (profit) each year or ($0.83) on an earnings per share basis. Infinity Pharmaceuticals employs 25 workers across the globe. What is Infinity Pharmaceuticals' official website? The official website for Infinity Pharmaceuticals is www.infi.com. How can I contact Infinity Pharmaceuticals? Infinity Pharmaceuticals' mailing address is 1100 MASSACHUSETTS AVENUE FLOOR 4, CAMBRIDGE MA, 02138. The biotechnology company can be reached via phone at 617-453-1000 or via email at [email protected] This page was last updated on 9/22/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
